- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03558932
IP3R Modulation by Cancer Genes in Mesothelioma
June 5, 2018 updated by: Yserbyt Jonas, KU Leuven
IP3R Modulation by Cancer Genes Bcl-2 & PKM2 in Mesothelioma
Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jonas Yserbyt
- Phone Number: +32 16 34 68 01
- Email: jonas.yserbyt@uzleuven.be
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 89 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
mesothelioma
Description
Inclusion Criteria:
- suspicion of mesothelioma
- referral for diagnostic thoracoscopy
Exclusion Criteria:
- contra-indication for thoracoscopy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pleural biopsy
Time Frame: 5 years
|
Biopsy
|
5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunoblotting
Time Frame: 5 years
|
biopsy
|
5 years
|
Cytometric analysis (FACS-based approaches)
Time Frame: 5 years
|
biopsy
|
5 years
|
Live cell imaging for Ca2+-signaling
Time Frame: 5 years
|
biopsy
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jonas Yserbyt, Catholic University Leuven
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2019
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
June 1, 2024
Study Registration Dates
First Submitted
May 23, 2018
First Submitted That Met QC Criteria
June 5, 2018
First Posted (Actual)
June 15, 2018
Study Record Updates
Last Update Posted (Actual)
June 15, 2018
Last Update Submitted That Met QC Criteria
June 5, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IP3mesov1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Mesothelioma
-
National Cancer Institute (NCI)CompletedRecurrent Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant MesotheliomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Malignant Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant MesotheliomaUnited States
-
University of ChicagoNational Cancer Institute (NCI)Active, not recruitingBiphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingBiphasic Mesothelioma | Epithelioid Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage I Pleural Malignant Mesothelioma AJCC v7 | Stage IA Pleural Malignant Mesothelioma AJCC v7 | Stage IB Pleural Malignant Mesothelioma AJCC v7 | Stage II Pleural Malignant Mesothelioma AJCC...United States
-
National Cancer Institute (NCI)CompletedCediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By SurgeryRecurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant MesotheliomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Localized Malignant MesotheliomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)TerminatedPleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Stage I Pleural Malignant Mesothelioma AJCC v8 | Stage IA Pleural Malignant Mesothelioma AJCC v8 | Stage IB Pleural Malignant Mesothelioma AJCC v8 | Stage II Pleural Malignant Mesothelioma AJCC v8 | Stage IIIA Pleural Malignant...United States, Canada
-
National Cancer Institute (NCI)CompletedRecurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant MesotheliomaUnited States
-
National Cancer Institute (NCI)WithdrawnAMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural MesotheliomaRecurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma
-
National Cancer Institute (NCI)Active, not recruitingEpithelioid Mesothelioma | Pleural Malignant Mesothelioma | Sarcomatoid Mesothelioma | Recurrent Malignant MesotheliomaUnited States
Clinical Trials on pleural biopsy
-
China-Japan Friendship HospitalRecruiting
-
University of OxfordCompleted
-
Eskisehir Osmangazi UniversityCompletedPleural DiseasesTurkey
-
Postgraduate Institute of Medical Education and...CompletedTuberculosis | Pleural Effusion | Pleurisy | Metastatic MalignancyIndia
-
Assiut UniversityNot yet recruitingDisorder of Pleura and Pleural Cavity
-
Eskisehir Osmangazi UniversityCompletedPleural Diseases | Pleural EffusionTurkey
-
Eskisehir Osmangazi UniversityCompletedDiagnosis of Pleural DiseasesTurkey
-
Medical University of WarsawNalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy...CompletedPleural Effusion | Exudative PleuritisPoland
-
Wuhan YZY Biopharma Co., Ltd.Not yet recruitingA Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCNSCLC Stage IV | Malignant Pleural EffusionsChina
-
University of OxfordBeckton DickinsonRecruitingPneumothorax | Pleural Diseases | Pleural Neoplasms | Pleural Effusion, Malignant | Pleural Effusion | Procedural Complication | Pleural Infection | Pleural Mesothelioma | Complications, Pulmonary | Pleural MetastasesUnited Kingdom